Quarterly Report Q2 2018

August 16, 2018

An Overview of the Prometic Quarterly Report

  • Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen)
  • Submitted plan to FDA regarding filing of the amended BLA for RyplazimTM (plasminogen)
  • Q2 revenues of $20.2 million, and net loss of $33.1 million. R&D and Admin costs down from the same period in 2017.
  • Received Rare Pediatric Disease Designation for PBI-4050 from the FDA for the treatment of Alström Syndrome
  • Presented new clinical data for PBI-4050 and PBI-4547 in liver fibrosis and for IVIG in PIDD demonstrating signs of positive clinical activity at several scientific conferences
Previous Flipbook
Quarterly Report Q3 2018
Quarterly Report Q3 2018

• Extension of maturity dates of Line of Credit and OID Loans to September 2024 • Implementation of cost co...

Next Flipbook
Notice of Annual and Special Meeting of Shareholders and Management Information Circular March 22, 2018
Notice of Annual and Special Meeting of Shareholders and Management Information Circular March 22, 2018

Notice of Annual and Special Meeting of Shareholders and Management Information Circular March 22, 2018